E2LDX: E2 and LDX for the Treatment of Cognitive Complaints After Oophorectomy

Sponsor

University of Pennsylvania (Other)

Overall Status

Withdrawn

CT.gov ID

NCT01986764

Collaborator

(none)

Enrollment

Location

Arms

Study Details

Study Description

Brief Summary

This project seeks to address cognitive disturbance, which is a frequent adverse sequelae of riskreducing bilateral salpingo-oophorectomy (RRSO) with or without post-procedure chemotherapy and adjunctive treatments. RRSO after completion of childbearing is recommended for prevention of ovarian and breast cancer in women with BRCA1/BRCA2 mutations and standard of care for women with some forms of hormone-responsive cancer. Knowledge regarding the impact of this procedure, with or without chemotherapy, and subsequent hypogonadism on brain health is less than adequate. Premenopausal women who undergo an acute surgical menopause are at greater risk for verbal memory decline and executive function (EF) complaints, but as of yet, we cannot predict who is going to experience these adverse sequelae, nor do we have targeted prevention or treatment strategies other than hormone therapy, which is not an option in many cases and not always effective. An idealized sample as women who are planning for a RRSO will undergo brain imaging and behavioral assessments pre- and post-surgery as well as pre-/post-treatment with E2 or the psychostimulant, lisdexamphetamine (LDX; Vyvanse®).

Condition or Disease	Intervention/Treatment	Phase
Planned RRSO	Drug: Lisdexamfetamine Drug: Estradiol Drug: Placebo	N/A

Study Design

Study Type:

Interventional

Actual Enrollment :

0 participants

Allocation:

Randomized

Intervention Model:

Factorial Assignment

Masking:

Triple (Participant, Investigator, Outcomes Assessor)

Primary Purpose:

Prevention

Official Title:

Predictors of Healthy Mood and Memory After Oophorectomy

Actual Study Start Date :

Jul 1, 2013

Actual Primary Completion Date :

Jul 1, 2013

Actual Study Completion Date :

Jul 1, 2013

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: lisdexamfetamine lisdexamfetamine 20 mg/d to 60 mg/d for 12 weeks	Drug: Lisdexamfetamine Other Names: Vyvanse
Active Comparator: Estradiol Estradiol 1 mg/d to 3 mg/d for 12 weeks	Drug: Estradiol Other Names: Estrogen
Placebo Comparator: Placebo	Drug: Placebo Placebo capsules will be filled with lactose powder.

Arm

Intervention/Treatment

Active Comparator: lisdexamfetamine

lisdexamfetamine 20 mg/d to 60 mg/d for 12 weeks

Drug: Lisdexamfetamine

Other Names:

Vyvanse

Active Comparator: Estradiol

Estradiol 1 mg/d to 3 mg/d for 12 weeks

Drug: Estradiol

Other Names:

Estrogen

Placebo Comparator: Placebo

Drug: Placebo

Placebo capsules will be filled with lactose powder.

Outcome Measures

Primary Outcome Measures

BADDS Score [12 weeks]
This study uses a double-blind, placebo-controlled, design. The primary subjective outcome variable is the BADDS score measured at the initial screening visit, and one week after oophorectomy and 12 weeks after randomization to E2, LDX or placebo post-oophorectomy. The primary, out-of-scan objective outcome will be performance on the HVLT, while the primary, in-scanner outcomes will be behavioral and brain activation measures during performance of the N-back task.

Secondary Outcome Measures

Cognitive Functioning [12 weeks]
The secondary outcome variable studies changes in memory assessed using a battery of cognitive tasks.

Eligibility Criteria

Criteria

Ages Eligible for Study:

30 Years to 48 Years

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Women ages 30 to 48 will be eligible for this study if they:

Have no previous or present history of a DSM-IV psychiatric disorder within the previous year or substance dependence disorder within the previous 5 years (psychostimulant abuse lifetime history), according to the Structured Clinical Interview for Diagnosis- DSM-IV (SCID)-Non-Patient Version;
Planning to undergo an oophorectomy or full hysterectomy;
Are premenopaual (have a baseline follicle stimulating hormone level (FSH) of <20 IU/ml);
Smoke < 10 cigarettes per day
Are right-handed;
Can provide proof of having had a gynecological exam and PAP test done within the previous 3 years at the time of screening;
Can provide proof of having had a mammogram within the previous 12 months at the time of screening;
Are able to give written informed consent;
Must have clear urine toxicology screen upon recruitment;
Are fluent in written and spoken English;
Negative urine pregnancy test.

Exclusion Criteria:

Mini-mental status exam score of less than or equal to 24;
Presence of a psychiatric disorder within previous year or a life time history of ADHD or psychotic disorder including bipolar disorder, schizoaffective disorder and schizophrenia;
Lifetime history of drug addiction or abuse, excepting nicotine;
Regular use of other psychotropic medication;
Regular use (more than once a week) of alcohol that is greater than 3 drinks per day;
Presence of a contraindication to treatment with stimulant medication; this would include the presence of hypertension (controlled or uncontrolled), coronary disease, atrial fibrillation, and arrhythmia;
History of seizures;
Presence of a contraindication to treatment with estrogen; this would include the presence of a history of blood clots, and estrogen-receptor positive breast cancer;
Claustrophobia;
History of cardiac disease including known cardiac defect or conduction abnormality;
Abnormal electrocardiogram during screening;
Current pregnancy or planning to become pregnant;
Presence of a metallic implant